Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
ORLANDO, FL / ACCESSWIRE / November 8, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that it has signed a supplier agreement with market leading kinesiology tape company, KT Tape. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer for a new line of specialized KT tape.
佛羅里達州奧蘭多/ACCESSWIRE /2023 年 11 月 8 日/ Nutriband Inc.(納斯達克股票代碼:NTRB)(納斯達克股票代碼:NTRBW)今天宣佈,它已與市場領先的運動機能學膠帶公司KT Tape簽署了供應商協議。Nutriband Inc. '其全資合同製造子公司Active Intelligence將擔任新系列專業KT磁帶的製造商。
Founded in 2008, KT Tape has revolutionized the sports medicine industry with the introduction of the most advanced and recognized kinesiology tape and recovery products in the world. KT Tape is recognized as a leader in sports-related drug-free pain and injury treatment. The mission of the company is to develop breakthrough solutions to help enable athletes and fitness enthusiasts to perform at their best. KT Tape is currently available in over 40,000 stores in the US and across the world. KT is also widely used by many major sports franchises throughout the US.
KT Tape 成立於 2008 年 通過引入世界上最先進、最受認可的肌內效學膠帶和恢復產品,徹底改變了運動醫學行業。KT Tape被公認爲運動相關無藥物疼痛和損傷治療領域的領導者。該公司的使命是開發突破性的解決方案,幫助運動員和健身愛好者發揮最佳表現。KT Tape目前在美國和世界各地的40,000多家商店有售。KT還被美國許多主要體育特許經營權廣泛使用。
"This supplier agreement with KT Tape allows Nutriband and our contract manufacturing subsidiary, Active Intelligence, to showcase our capabilities in the development and manufacturing of innovative new product technologies with one of the world's largest brands" said Gareth Sheridan, CEO of Nutriband.
Nutriband首席執行官Gareth Sheridan表示:“這份與KT Tape的供應商協議使Nutriband和我們的合同製造子公司Active Intelligence能夠展示我們在與全球最大的品牌之一合作開發和製造創新產品技術方面的能力。”
About Nutriband Inc.
關於 Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA technology. Aversa is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, specifically opioids.
我們主要從事透皮藥物產品組合的開發。我們正在開發的主要產品是一款含有我們的 AVERSA 的防濫用芬太尼補丁 技術。Aversa是一種抑制濫用的透皮技術,它含有厭惡藥物,可防止可能被濫用的藥物,特別是阿片類藥物的濫用、轉移、濫用和意外接觸。
The Company's website is . Any material contained in or derived from the Company's websites or any other website is not part of this press release.
該公司的網站是。公司網站或任何其他網站中包含或衍生的任何材料均不屬於本新聞稿的一部分。
About Our Forward-Looking Statements
關於我們的前瞻性陳述
Certain statements contained in this press release, including, without limitation, statements containing the words ''believes,'' "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an under capitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2022 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
本新聞稿中包含的某些陳述,包括但不限於包含 “相信”、“預期”、“期望” 等詞語和類似含義的言論,構成1995年《私人證券訴訟改革法》所指的 “前瞻性陳述”。此類前瞻性陳述涉及已知和未知的風險和不確定性。公司的實際業績可能與其前瞻性陳述中的預期存在重大差異,這要歸因於多種因素,包括公司開發其擬議的濫用威懾芬太尼透皮系統和其他擬議產品的能力、其濫用技術獲得專利保護的能力、獲得開發產品和進行必要臨床測試所需的融資的能力、獲得聯邦食品藥品監督管理局批准銷售其任何產品的能力可能會發展在美國並獲得在其他國家(包括歐洲國家)銷售任何產品所必需的任何其他監管部門批准,其銷售可能開發的任何產品的能力,創造、維持、管理或預測其增長的能力;吸引和留住關鍵人員的能力;公司業務戰略或發展計劃的變化;競爭;業務中斷;負面影響以及國際、國家和地方總體經濟和市場狀況以及通常與資本不足相關的風險化開發公司,以及公司截至2022年1月31日止年度的S-1表格、10-K表格和10-Q表中 “風險因素” 和 “管理層對財務狀況和經營業績的討論與分析” 以及公司向美國證券交易委員會提交的其他文件中包含的風險。除非適用法律要求,否則我們沒有義務修改或更新任何前瞻性陳述以反映本文發佈之日後可能發生的任何事件或情況。
For more information, contact:
欲了解更多信息,請聯繫:
Patrick Ryan
CTO Nutriband Inc
paddyr@nutriband.com / support@nutriband.com
121 S Orange Ave, Orlando, FL, 32407
+1 (407) 377-6695
帕特里克·瑞
首席技術官 Nutriband Inc
paddyr@nutriband.com/support@nutriband.com
佛羅里達州奧蘭多市南奧蘭治大道 121 號,32407
+1 (407) 377-6695
SOURCE: Nutriband Inc.
來源: Nutriband Inc
譯文內容由第三人軟體翻譯。